| Autor: |
Kring TS; Department of Surgical Gastroenterology, Hvidovre Hospital, Hvidovre, Denmark., Piper TB; Department of Surgical Gastroenterology, Hvidovre Hospital, Hvidovre, Denmark., Jørgensen LN; Digestive Disease Center, Bispebjerg Hospital, Copenhagen, Denmark. ; Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Olsen J; Department of Surgical Gastroenterology, Glostrup Hospital, Glostrup, Denmark., Rahr HB; Department of Surgical Gastroenterology, Odense University Hospital, Odense, Denmark., Nielsen KT; Department of Surgery, Randers Hospital, Randers, Denmark., Laurberg S; Department of Surgical Gastroenterology, Aarhus Hospital THG, Aarhus, Denmark., Davis G; Abbott Diagnostics Division R&D, Chicago, USA., Dowell B; Abbott Diagnostics Division R&D, Chicago, USA., Johansen JS; Department of Oncology, Herlev Hospital, Herlev, Denmark., Christensen IJ; Department of Surgical Gastroenterology, Hvidovre Hospital, Hvidovre, Denmark., Brünner N; Institute of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg, Denmark., Nielsen HJ; Department of Surgical Gastroenterology, Hvidovre Hospital, Hvidovre, Denmark. ; Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. |
| Abstrakt: |
Soluble cancer-related protein biomarker levels may be increased in subjects without findings at large bowel endoscopy performed due to symptoms associated with colorectal cancer. The present study focused on a possible association between increased biomarker levels in such subjects and subsequent development of malignant diseases. In a major study of 4,990 subjects undergoing large bowel endoscopy, 691 were without pathology and comorbidity. Plasma levels of TIMP-1, CEA, CA19-9, and YKL-40 were determined in samples collected just before endoscopy and compared with subsequent development of a malignant disease within a period of 7-8 years. The upper 90% limits of the reference levels of every single protein were used to differentiate between normal and increased levels. The levels were separated into three groups: 0, none of the biomarkers increased; 1, one biomarker increased; 2, two or more biomarkers increased. A total of 43 subjects developed a primary malignant disease in the observation period. Univariatly, increase of all four biomarkers was significantly associated with subsequent development of a malignant disease. A multivariate analysis showed that increased biomarker levels were associated with subsequent development of a malignant disease (P = 0.002). The cumulative risk of developing malignant disease within the first 5 years after endoscopy was group 0, 3.3%; group 1, 5.8%; group 2, 7.8%. It is concluded that increased levels of plasma TIMP-1, CEA, CA19-9, and serum YKL-40 at large bowel endoscopy without findings may be associated with an increased risk of developing a subsequent malignant disease. |
